Enzo Biochem, Inc. (NYSE:ENZ) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.
On June 8, 2017, Enzo Biochem, Inc. (the Company) issued a press
release announcing its operating results for its third fiscal
quarter ended April 30, 2017. A copy of the press release is
furnished as Exhibit 99.1 attached hereto and is incorporated by
reference in its entirety into this item 2.02 of this Current
Report on Form 8-K.
In its press release, the Company discloses items not prepared in
accordance with accounting principles generally accepted in the
United States (GAAP), or non-GAAP financial measures (as defined
in Regulation G promulgated by the U.S. Securities and Exchange
Commission) that exclude certain significant charges or credits
that are important to an understanding of the Companys ongoing
operations. The Company believes that its inclusion of non-GAAP
financial measures provides useful supplementary information to
and facilitates analysis by investors in evaluating the Companys
performance and trends. The determination of significant charges
or credits may not be comparable to similar measures used by
other companies and may vary from period to period. The Company
uses both GAAP financial measures and the disclosed non-GAAP
financial measures internally to evaluate and manage the Companys
operations and to better understand its business. These non-GAAP
financial measures are in addition to, not a substitute for, or
superior to, measures of financial performance prepared in
accordance with GAAP.
Non-GAAP net income, non-GAAP earnings per share, and adjusted
EBITDA are supplemental measures of our performance that are not
required by, or presented in accordance with, GAAP. We define
non-GAAP net income as consolidated net income / (loss) for such
period adjusted for the following net of tax (i) litigation
charges and settlements, (ii) business restructuring or other
restructurings of a similar nature, and (iii) other unusual
charges or expenses. We define adjusted EBITDA as an amount equal
to consolidated net income / (loss) for such period adjusted for
the following (i) interest expense, (ii) interest income, (iii)
provision for income taxes, (iv) depreciation and amortization
expenses, (v) litigation charges and settlements, (vi) business
restructuring charges or other restructurings of a similar
nature, and (vii) other unusual charges or expenses.
Item 7.01. Regulation FD Disclosure.
The information provided in Item 2.02 of this Current Report on
Form 8-K is incorporated herein by reference in its entirety.
The information discussed under Item 2.02 and Item 7.01 above,
including Exhibit 99.1, shall not be deemed filed for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended, or
incorporated by reference in any filing by the Company under the
Securities Act of 1933, as amended, except as shall be expressly
set forth by specific reference in such a filing.
The information in this report (including the exhibits) is
furnished to Item 2.02 and shall not be deemed to be filed for
purposes of Section 18 of the Securities Exchange Act of 1934
(the Exchange Act), nor shall it be deemed incorporated by
reference in any filing under the Securities Act of 1933 or the
Exchange Act, except as shall be expressly set forth by specific
reference in such filing.
Item 8.01 Other events
On June 8, 2017, Enzo Biochem, Inc. (the Company) issued a press
release titled Enzo Biochem Announces New York State Health
Department Approval of New Womens Health Diagnostics
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
| 99.1 | Press Release of Enzo Biochem, Inc., dated June 8, 2017. |
| 99.2 | Press Release of Enzo Biochem, Inc., dated June 8, 2017. |
About Enzo Biochem, Inc. (NYSE:ENZ)
Enzo Biochem, Inc. is a bioscience company focusing on delivering and applying technology capabilities to produce products and services. The Company’s segments include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. Enzo Clinical Labs is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies. It offers a menu of molecular and other clinical laboratory tests or procedures. Enzo Life Sciences manufactures, develops and markets products and tools to clinical research, drug development and bioscience research customers. Enzo Therapeutics is a biopharmaceutical venture that develops multiple approaches in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases. Its products in the development pipeline include a range of assays for detection of various women’s health infectious agents, as well as for use in the identification of pathogens for other markets.
